Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: A post-hoc analysis of the WISDOM trial

The Lancet Respiratory Medicine

Volumn 4, Issue 5, 2016, Pages 390-398

  Watz, Henrik ^a   Tetzlaff, Kay ^b,c   Wouters, Emiel F M ^d   Kirsten, Anne ^a   Magnussen, Helgo ^a   Rodriguez Roisin, Roberto ^e   Vogelmeier, Claus ^f   Fabbri, Leonardo M ^g   Chanez, Pascal ^h   Dahl, Ronald ⁱ   Disse, Bernd ^b   Finnigan, Helen ^j   Calverley, Peter M A ^k  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY HOSPITAL MARBURG   (Germany)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^j BOEHRINGER INGELHEIM LTD   (United Kingdom)

^k UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; SALMETEROL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; FLUTICASONE; SALMETEROL XINAFOATE;

ADULT; ARTICLE; ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRICK TEST; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; BLOOD; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EOSINOPHIL; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EOSINOPHILS; FEMALE; FLUTICASONE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84964388893     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)00100-4     Document Type: Article

References (27)

1. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303.
2. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013, 1:210-223.
3. Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015, 12:27-34.
4. Price D, Yawn B, Brusselle G, Rossi A Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013, 22:92-100.
5. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26.
6. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. A randomized placebo-controlled trial. Am J Respir Crit Care Med 2012, 186:48-55.
7. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014, 44:789-791.
8. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015, 3:435-442.
9. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015, 192:523-525.
10. Magnussen H, Watz H, Kirsten A, et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med 2014, 108:593-599.
11. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014, 371:1285-1294.
12. Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014, 2:891-901.
13. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG Blood eosinophils and exacerbations in COPD: the Copenhagen General Population Study. Am J Respir Crit Care Med 2015, published online Dec 7. 10.1164/rccm.201509-1869OC.
14. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 2016, 71:118-125.
15. Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015, 3:849-858.
16. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 2010, 104:1460-1472.
17. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
18. Martinez FJ, Calverley PMA, Goehring U-M, Brose M, Fabbri LM, Rabe KF Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015, 385:857-866.
19. Calverley P Knowing when to stop: inhaled corticosteroids and COPD. Eur Respir J 2015, 46:1236-1238.
20. Suissa S and Rossi A Weaning from inhaled corticosteroids in COPD: the evidence. Eur Respir J 2015, 46:1232-1235.
21. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014, 44:1697-1700.
22. Barnes PJ Corticosteroids, IgE, and atopy. J Clin Invest 2001, 107:265-266.
23. Fattahi F, ten Hacken NH, Lofdahl CG, et al. Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study. Respir Res 2013, 14:10.
24. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011, 5:44-49.
25. Calverley PMA, Spencer S, Willits L, Burge PS, Jones PW Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003, 124:1350-1356. on behalf of the ISOLDE Study Group.
26. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med 2013, 107:550-559.
27. Busch R, Han MK, Bowler RP, et al. Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. BMC Pulm Med 2016, 16:28.